Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Clea Shearer opens up to PEOPLE about the latest and unexpected surgery in her breast cancer journey, and how she’s using her ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

A Lilly USA LLC employee fired for allegedly misusing a corporate credit card failed to mount a viable claim that he was ...

Patients using Eli Lilly’s Mounjaro are being reminded that the KwikPen injection devices should be discarded after four doses ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

Highlights,Institutional ownership in Eli Lilly, (NYSE:LLY),has seen an increase, with multiple firms adding to their ...

Highlights,Institutional investors have adjusted their positions in Eli Lilly and Company, (NYSE:LLY),, reflecting ongoing ...

There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...

Two healthcare stocks that may or may not be boring, but that regardless look like strong growth stocks to invest in this ...